diphenhydramine has been researched along with Alcohol Drinking in 12 studies
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diphenhydramine poisoning is characterized most often by anticholinergic effects." | 7.68 | Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. ( Clark, RF; Vance, MV, 1992) |
| "Diphenhydramine poisoning is characterized most often by anticholinergic effects." | 3.68 | Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. ( Clark, RF; Vance, MV, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogenschutz, MP | 2 |
| Ross, S | 2 |
| Bhatt, S | 1 |
| Baron, T | 2 |
| Forcehimes, AA | 2 |
| Laska, E | 1 |
| Mennenga, SE | 2 |
| O'Donnell, K | 1 |
| Owens, LT | 2 |
| Podrebarac, S | 1 |
| Rotrosen, J | 2 |
| Tonigan, JS | 1 |
| Worth, L | 1 |
| O'Donnell, KC | 1 |
| Podrebarac, SK | 1 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Huang, Z | 1 |
| Liu, T | 1 |
| Li, Y | 1 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Chen, Y | 1 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 1 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Cheng, X | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Wang, W | 2 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhang, H | 1 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 1 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 1 |
| Gu, Y | 1 |
| Chen, C | 1 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Zhu, P | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Wang, Z | 1 |
| Xie, B | 1 |
| Song, T | 1 |
| Zhang, F | 1 |
| Luo, A | 1 |
| Li, S | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Huang, L | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Liu, L | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 1 |
| Niu, X | 1 |
| Liu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Zhang, Y | 1 |
| Li, J | 2 |
| Zhao, M | 1 |
| Zhao, J | 1 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 1 |
| Li, R | 1 |
| Zhao, D | 1 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 1 |
| Luo, Y | 1 |
| Zheng, D | 1 |
| Xie, L | 1 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| Brubacher, JR | 1 |
| Chan, H | 1 |
| Martz, W | 1 |
| Schreiber, W | 1 |
| Asbridge, M | 1 |
| Eppler, J | 1 |
| Lund, A | 1 |
| Macdonald, S | 1 |
| Drummer, O | 1 |
| Purssell, R | 1 |
| Andolfatto, G | 1 |
| Mann, R | 1 |
| Brant, R | 1 |
| Canfield, DV | 1 |
| Dubowski, KM | 1 |
| Chaturvedi, AK | 1 |
| Whinnery, JE | 1 |
| Handel, DA | 1 |
| Raja, A | 1 |
| Lindsell, CJ | 1 |
| Doenecke, AL | 1 |
| Heuermann, RC | 1 |
| Plueckhahn, VD | 1 |
| Clark, RF | 1 |
| Vance, MV | 1 |
| Messiha, FS | 1 |
| Pasi, A | 1 |
| Calvert, RT | 1 |
| Parry, R | 1 |
| Forney, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence[NCT02061293] | Phase 2 | 95 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms[NCT06160232] | Phase 2 | 62 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Baseline (Week 4)
| Intervention | drinks per day (Mean) |
|---|---|
| Psilocybin | 2.77 |
| Diphenhydramine | 2.19 |
The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)
| Intervention | drinks per day (Mean) |
|---|---|
| Psilocybin | 1.17 |
| Diphenhydramine | 2.26 |
The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Screening (Week 0)
| Intervention | drinks per day (Mean) |
|---|---|
| Psilocybin | 5.2 |
| Diphenhydramine | 4.38 |
The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Baseline (Week 4)
| Intervention | percentage of days (Mean) |
|---|---|
| Psilocybin | 52.98 |
| Diphenhydramine | 45.99 |
The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)
| Intervention | percentage of days (Mean) |
|---|---|
| Psilocybin | 29.39 |
| Diphenhydramine | 42.83 |
The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Screening (Week 0)
| Intervention | percentage of days (Mean) |
|---|---|
| Psilocybin | 78.03 |
| Diphenhydramine | 71.68 |
The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Baseline (Week 4)
| Intervention | percentage of days (Mean) |
|---|---|
| Psilocybin | 24.11 |
| Diphenhydramine | 21.31 |
The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)
| Intervention | percentage of days (Mean) |
|---|---|
| Psilocybin | 9.71 |
| Diphenhydramine | 23.57 |
The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Screening (Week 0)
| Intervention | percentage of days (Mean) |
|---|---|
| Psilocybin | 56.48 |
| Diphenhydramine | 48.57 |
The Timeline Follow-back (TLFB) method is used in calculating the number of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: From Week 33 Up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 62.5 |
| Diphenhydramine | 40 |
The Timeline Follow-back (TLFB) method is used in calculating the number of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 33.3 |
| Diphenhydramine | 11.1 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 Up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 89.6 |
| Diphenhydramine | 64.4 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 83.3 |
| Diphenhydramine | 71.1 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 Up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 60.4 |
| Diphenhydramine | 40 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 60.4 |
| Diphenhydramine | 40 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 37.5 |
| Diphenhydramine | 17.8 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 29.92 |
| Diphenhydramine | 13.3 |
The Timeline Follow-back (TLFB) method is used in calculating abstinence from drinking. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Abstinence is defined as zero drinks of alcohol over the target period. (NCT02061293)
Timeframe: From Week 33 up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 47.9 |
| Diphenhydramine | 24.4 |
The Timeline Follow-back (TLFB) method is used in calculating abstinence from drinking. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Abstinence is defined as zero drinks of alcohol over the target period. (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Psilocybin | 22.9 |
| Diphenhydramine | 8.9 |
15-item self-report questionnaire assessing problems related to alcohol use. Items are ranked on a 4-point Likert scale ranging from 0 (never) to 3 (daily or almost daily). The total score range is 0-45; the higher the score, the more problems related to alcohol use. (NCT02061293)
Timeframe: Baseline (Week 4)
| Intervention | score on a scale (Mean) |
|---|---|
| Psilocybin | 20.26 |
| Diphenhydramine | 21.6 |
15-item self-report questionnaire assessing problems related to alcohol use. Items are ranked on a 4-point Likert scale ranging from 0 (never) to 3 (daily or almost daily). The total score range is 0-45; the higher the score, the more problems related to alcohol use. (NCT02061293)
Timeframe: Week 36
| Intervention | score on a scale (Mean) |
|---|---|
| Psilocybin | 6.59 |
| Diphenhydramine | 13 |
1 review available for diphenhydramine and Alcohol Drinking
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
3 trials available for diphenhydramine and Alcohol Drinking
| Article | Year |
|---|---|
Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.
Topics: Alcohol Drinking; Alcoholism; Diphenhydramine; Humans; Psilocybin; Treatment Outcome | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
International seminar research on alcohol, drugs and driving.
Topics: Alcohol Drinking; Auditory Perception; Automobile Driving; Caffeine; Chlordiazepoxide; Clinical Tria | 1973 |
9 other studies available for diphenhydramine and Alcohol Drinking
| Article | Year |
|---|---|
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Prevalence of alcohol and drug use in injured British Columbia drivers.
Topics: Accidents, Traffic; Adult; Alcohol Drinking; Antidepressive Agents; Benzodiazepines; British Columbi | 2016 |
Drugs and alcohol found in civil aviation accident pilot fatalities from 2004-2008.
Topics: Accidents, Aviation; Adult; Alcohol Drinking; Diphenhydramine; Female; Humans; Male; Middle Aged; No | 2012 |
The use of sleep aids among Emergency Medicine residents: a web based survey.
Topics: Adult; Alcohol Drinking; Analgesics; Anti-Anxiety Agents; Diphenhydramine; Disorders of Excessive So | 2006 |
Treatment of haloperidol abuse with diphenhydramine.
Topics: Adolescent; Adult; Alcohol Drinking; Diazepam; Diphenhydramine; Female; Haloperidol; Humans; Male; S | 1980 |
Alcohol and road safety: Geelong experience 1967 to 1978.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Australia; Automobile Dri | 1978 |
Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate.
Topics: Adolescent; Alcohol Drinking; Bicarbonates; Blood Gas Analysis; Charcoal; Diphenhydramine; Electroca | 1992 |
Behavioral and metabolic adverse interactions between diphenhydramine and ethanol.
Topics: Alcohol Dehydrogenase; Alcohol Drinking; Aldehyde Dehydrogenase; Animals; Behavior, Animal; Diphenhy | 1991 |
The effect of alcohol intake on the disposition of diphenhydramine in man.
Topics: Administration, Oral; Adult; Alcohol Drinking; Biotransformation; Diphenhydramine; Ethanol; Half-Lif | 1986 |